What is claimed is:

1. An anti-aPC monoclonal antibody, wherein the anti-aPC monoclonal antibody is selected from one of the following:

an antibody comprising (c) heavy chain CDRs represented by SEQ ID NOs: 33, 34 and 35; and/or (d) light chain CDRs represented by SEQ ID NOs: 36, 37 and 38;

an antibody comprising (e) heavy chain CDRs represented by SEQ ID NOs: 39, 40 and 41; and/or (f) light chain CDRs represented by SEQ ID NOs: 42, 43 and 44;

an antibody comprising (g) heavy chain CDRs represented by SEQ ID NOs: 45, 46 and 47; and/or (h) light chain CDRs represented by SEQ ID NOs: 48, 49 and 50;

an antibody comprising (i) heavy chain CDRs represented by SEQ ID NOs: 51, 52 and 53; and/or (j) light chain CDRs represented by SEQ ID NOs: 54, 55 and 56;

an antibody comprising (k) heavy chain CDRs represented by SEQ ID NOs: 57, 58 and 59; and/or (l) light chain CDRs represented by SEQ ID NOs: 60, 61 and 62;

an antibody comprising (m) heavy chain CDRs represented by SEQ ID NOs: 63, 64 and 65; and/or (n) light chain CDRs represented by SEQ ID NOs: 66, 67 and 68;

an antibody comprising (o) heavy chain CDRs represented by SEQ ID NOs: 69, 70 and 71; and/or (p) light chain CDRs represented by SEQ ID NOs: 72, 73 and 74;

an antibody comprising (q) heavy chain CDRs represented by SEQ ID NOs: 75, 76 and 77; and/or (r) light chain CDRs represented by SEQ ID NOs: 78, 79 and 80;

an antibody comprising (s) heavy chain CDRs represented by SEQ ID NOs: 81, 82 and 83; and/or (t) light chain CDRs represented by SEQ ID NOs: 84, 85 and 86; and

an antibody comprising (u) heavy chain CDRs represented by SEQ ID NOs: 87, 88 and 89; and/or (v) light chain CDRs represented by SEQ ID NOs: 90, 91 and 92.

2. The anti-aPC monoclonal antibody according to claim 1, comprising:

a heavy chain as shown in any of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25; and/or

a light chain as shown in any of SEQ ID NOs: 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26.

3. The anti-aPC monoclonal antibody according to claim 1, wherein the anti-aPC monoclonal antibody is selected from the following:

an antibody comprising a heavy chain as shown in SEQ ID NO: 7 and a light chain as shown in SEQ ID NO: 8;

an antibody comprising a heavy chain as shown in SEQ ID NO: 9 and a light chain as shown in SEQ ID NO: 10;

an antibody comprising a heavy chain as shown in SEQ ID NO: 11 and a light chain as shown in SEQ ID NO: 12;

an antibody comprising a heavy chain as shown in SEQ ID NO: 13 and a light chain as shown in SEQ ID NO: 14;

an antibody comprising a heavy chain as shown in SEQ ID NO: 15 and a light chain as shown in SEQ ID NO: 16;

an antibody comprising a heavy chain as shown in SEQ ID NO: 17 and a light chain as shown in SEQ ID NO: 18;

an antibody comprising a heavy chain as shown in SEQ ID NO: 19 and a light chain as shown in SEQ ID NO: 20;

an antibody comprising a heavy chain as shown in SEQ ID NO: 21 and a light chain as shown in SEQ ID NO: 22;

an antibody comprising a heavy chain as shown in SEQ ID NO: 23 and a light chain as shown in SEQ ID NO: 24; and

an antibody comprising a heavy chain as shown in SEQ ID NO: 25 and a light chain as shown in SEQ ID NO: 26.

4. The anti-aPC monoclonal antibody according to claim 1, wherein the anti-aPC monoclonal antibody is a complete antibody or an antibody fragment thereof; wherein the antibody fragment is Fab', Fab, F(ab')2, Fv or scFv.

5. A biological material related to the anti-aPC monoclonal antibody according to any one of claims 1 to 4, wherein the biological material is any one of 1) to 3) as follows:

1) a nucleic acid molecule encoding the anti-aPC monoclonal antibody according to claim 1;

2) a construct containing the nucleic acid molecule as described in 1); and

3) an expression system containing the nucleic acid molecule as described in 1).

6. A preparation product, wherein the preparation product is a pharmaceutical composition or a detection kit;

the preparation product comprises the anti-aPC monoclonal antibody according to claim 1 or any one or more of the biological materials according to claim 5; and

when being the pharmaceutical composition, the preparation product further comprises a pharmaceutically acceptable carrier.

7. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use in treating coagulation related disorders of an individual, wherein the individual suffers from coagulation deficiency or defect disorders, or the individual is in need of blood coagulation treatment, or the individual suffers from sepsis or hemophilia, or the individual is in need of regulation of hemostasis.

8. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use as a drug for the prevention and/or treatment of coagulation deficiency or defect disorders.

9. The use according to claim 8, wherein the coagulation deficiency or defect disorders comprise disorders causing coagulopathy due to deficiency of coagulation factors and thus causing bleeding, and coagulation disturbances caused by trauma or surgery.

10. The use according to claim 8, wherein the coagulation deficiency or defect disorders comprise hemophilia, sepsis and traumatic hemorrhage.

11. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use as a promoter for promoting an ability of aPC to cleave histones H3 and H4.

12. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use as a drug for inhibiting anticoagulant activity of activated protein C in an individual.

13. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use as a drug for the treatment in an individual in need of blood coagulation.

14. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use as a drug for regulating hemostasis in an individual.

15. The anti-aPC monoclonal antibody according to any one of claims 1 to 4 or the biological material according to claim 5 for use as a detection reagent or kit for aPC.